A comparison of four fibrosis indexes in chronic HCV: Development of new fibrosis-cirrhosis index (FCI)

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Ahmad, Waqar ^a   Ijaz, Bushra ^a   Javed, Fouzia T ^b   Gull, Sana ^a   Kausar, Humaira ^a   Sarwar, Muhammad T ^a   Asad, Sultan ^a   Shahid, Imran ^a   Sumrin, Aleena ^a   Khaliq, Saba ^a   Jahan, Shah ^a   Pervaiz, Asim ^a   Hassan, Sajida ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b JINNAH HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; SERUM ALBUMIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; VIRUS LOAD; ADULT; AREA UNDER THE CURVE; BIOPSY; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; ALANINE TRANSAMINASE; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOPSY; CHI-SQUARE DISTRIBUTION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; ROC CURVE; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; VIRAL LOAD; YOUNG ADULT;

EID: 79954625873     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-44     Document Type: Article

References (57)

1. Giannini C, Brechot C. Hepatitis C virus biology. J Virology 2003, 10:S27-S38.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997, 26:62S-65S. 10.1002/hep.510260711, 9305666.
3. Raja NS, Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008, 41:4-8.
4. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008, 8:69. 10.1186/1471-2334-8-69, 2409346, 18498666.
5. EL-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-S83.
6. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Kpike K. The Core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-1077. 10.1038/2053, 9734402.
7. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358-1364. 10.1053/jhep.2001.24432, 11391523.
8. National Institute of health Consensus Development Conference Statement Management of Hepatitis C: 2002. Hepatology 2002, 36:973-977. National Institute of health Consensus Development Conference Statement.
9. Silva RG, Fakhouri R, Nascimento TV, Santos IM, Barbosa LM. Aspartate aminotransferase-to-Platelet ration index for fibrosis and cirrhosis prediction in chronic hepatitis C patients. Braz J Infect Dis 2008, 12:15-19.
10. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Eng J Med 2000, 342:1266-1271.
11. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006, 26:1095-1099. 10.1111/j.1478-3231.2006.01356.x, 17032410.
12. Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A. Vertical transmission of HCV is related to maternal peripheral blood mononucleat cell infection. Blood 2000, 96:2045-2048.
13. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Sluzewski W. Influence of the presence of HCV-RNA in peripheral blood mononuclear cells on the clinical course of chronic hepatitis C in children. Eur J Epidemiol 2007, 22:343-348. 10.1007/s10654-007-9125-2, 17484030.
14. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready. Lancet 2010, 375:1419-1420. 10.1016/S0140-6736(09)62195-4, 20417845.
15. Hoofnagle JH, Williams AL. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology 1988, 95:734-739.
16. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
17. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, makino Y, Araki Y, Shiratori Y. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006, 60:77-84.
18. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology 2007, 46:32-36. 10.1002/hep.21669, 17567829.
19. The French METAVIR Cooperative Study Group Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20. The French METAVIR Cooperative Study Group.
20. Poynard T, Bedossa P, Opolon P. Natural history of liver history of liver fibrosis progression in Patients with chronic hepatitis C. The OBVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832. 10.1016/S0140-6736(96)07642-8, 9121257.
21. Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, Hassan S. HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterology 2010, 16:4321-4328.
22. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996, 23:695-699. 10.1002/hep.510230406, 8666319.
23. Idrees M, Rafique S, Irshad-ur-rehman, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, akram M, Aftab M, Khubaib B, Riazuddin S. Hepatitis C genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gasteroenterol 2009, 15:5080-5085.
24. Mendes SCL, Nita EM, Ono-Nita KS, Mello SE, Silva CL, Alves VA, Carriho FJ. Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients. World J Gastroenterol 2008, 14:2522-2528. 10.3748/wjg.14.2522, 2708363, 18442199.
25. Tassopoulos NC, Papatheodoridis GV, Katsoulidou A, Delladetsima JK, Sypsa V, Touloumi G, Nikandros M, Hatzakis A. Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterology 1998, 45:1678-1683.
26. Ramalho F, Costa A, Pires A, Cabrita P, Sereojo F, Correia AP, Fatela N, Cloria H, Lopes J, Pinto HC, Marinho R, Raimundo M, Velosa J, Batista A, de Moura MC. Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci 2000, 45:182-187. 10.1023/A:1005442317680, 10695633.
27. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, Resta S. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997, 26:1393-1398.
28. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995, 90:1250-1257.
29. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002, 32:634-643.
30. Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S. Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. Int J Infect Dis 2002, 6:272-276. 10.1016/S1201-9712(02)90160-8, 12718820.
31. Shafique M, Ahmad N, Awan FR, Mustafa T, Ullah M, Qureshi JA. Investigating the concurrent presence of HCV in serum, oral fluid and urine samples from chronic HCV patients in Faisalabad, Pakistan. Arch Virol 2009, 154:1523-1527. 10.1007/s00705-009-0477-7, 19669078.
32. Mastoi AA, Devrajani BR, Shah SZA, Rohopoto Q, Memon SA, Baloch M, Qureshi GA, Sami W. Metabolic investigations in patients with hepatitis B and C. World J Gastroenterol 2010, 16:603-607. 10.3748/wjg.v16.i5.603, 2816273, 20128029.
33. Viroj W. High serum alkaline phosphatase levels, a study in 181 Thai adult hospitalized patients. BMC Family Practice 2001, 2:2. 10.1186/1471-2296-2-2, 55333, 11545676.
34. Saif MW, Alexander D, Wicox CM. Serum Alkaline Phosphatase Level as Prognostic Tool in Colorectal Cancer: A study of 105 patients. J Appl Res 2005, 5:88-95. 2741323, 19750205.
35. Lee GH, Benner D, Regidor DL, Kalatar-Zadeh K. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007, 17:38-44. 10.1053/j.jrn.2006.07.006, 17198930.
36. Raymond E, Boige V, Faivre S, Sanderink G, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP. Dosage adjustment and pharmacokinetic profile of Irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002, 20:4303-4312. 10.1200/JCO.2002.03.123, 12409328.
37. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075. 10.1016/S0140-6736(00)04258-6, 11297957.
38. Myres RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T, . MULTIVIRC Group Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003, 48:271-278. MULTIVIRC Group.
39. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Cuto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL, . HALT-C Trial Group Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gasteroenterology 2010, 138:136-146. HALT-C Trial Group.
40. Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis. J Gastroentrol Hepatol 2001, 16:777-781.
41. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001, 96:3053-3055. 10.1111/j.1572-0241.2001.05253.x, 11721749.
42. Fusegawa H, Shiraishi K, Ogasawara F, Shimizu M, Haruki Y, Miyachi H, Matsuzaki S, Ando Y. Platelet activation in patients with chronic hepatitis C. Tokai J Exp Clin Med 2002, 27:101-106.
43. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005, 41:1376-1382. 10.1002/hep.20717, 15915455.
44. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ration in assessing disease severity and prognosis in patients with hepatitis C virus related chronic liver disease. Arch Intern Med 2003, 163:218-224. 10.1001/archinte.163.2.218, 12546613.
45. Shaikh S, Memon MS, Ghani H, Baloch GH, Jaffery M, Shaikh K. Validation of Three Non-Invasive Markers in Assessing the Severity of Liver Fibrosis in Chronic Hepatitis C. JCPSP 2009, 19:478-482.
46. Khan DA, Fatima-Tuz-Zuhra, Khan FA, Mubarak A. Evaluation of diagnostic accuracy of apri for prediction of fibrosis in hepatitis c patients. J Ayub Med Coll Abbottabad 2008, 20:122-126.
47. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006, 40:535-542. 10.1097/00004836-200607000-00013, 16825937.
48. Macias J, Gonzalez J, Ortega E, Tural C, Cabrero E, Burgos A, Pineda JA, . GRAFIHCO Study Team Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. HIV Med 2010, 11:439-447. GRAFIHCO Study Team.
49. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski SM, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, . APRICOT Clinical Investigators Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325. 10.1002/hep.21178, 16729309, APRICOT Clinical Investigators.
50. Trang T, Petersen JR, Snyder N. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: Comparison of the APRI and FIB-4 index. Clinica Chimica Acta 2008, 397:51-54.
51. Forns X, Ampurdanes S, Liovet JM, Aponte J, Quinto L, Marteniz-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2003, 36:986-992.
52. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T, . MULTIVIRIC Group Biochemical markers of liver fibrosis: a comparison with histological features in patients with chronic hepatitis C. Am J Gasteroenterol 2002, 97:2419-2425. MULTIVIRIC Group.
53. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease 2. GUT 2006, 55:1650-1660. 10.1136/gut.2006.091454, 1860097, 17047111.
54. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatology 2006, 44:462-474.
55. Pinzani M. The ELF panel: a new crystal ball in hepatology?. Gut 2010, 59:1165-1167. 10.1136/gut.2010.214932, 20587543.
56. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS. Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 2009, 18:1914-1921. 10.1158/1055-9965.EPI-08-0980, 19454616.
57. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127(6):1704-1713. 10.1053/j.gastro.2004.08.052, 15578508.